LFVN at a glance
Lifevantage Corp (LFVN, SEC CIK 849146) filed its latest 10-K annual report on August 27, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2026 (FY2026), Lifevantage Corp (LFVN) reported revenue of $182.6 million (down 20.1% from FY2025) and net income of $5.1 million. Diluted EPS was $0.40.
- As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding Lifevantage Corp (LFVN) shares worth $12.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by BEINDORFF MICHAEL A on November 12, 2026 of 10,000 shares at $4.89 per share.
- In the last 90 days, LFVN insiders reported 1 open-market purchase ($6K) and 3 open-market sales ($105K) on Form 4, a net sale of $98K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $182.6M
- −20.1% vs prior year
- Insiders · 90 days
- 1 buy · 3 sells
- Net −$98K
- 13F holders
- 18 funds
- $12.5M · +0 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 5.07
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2025
Business Overview
- Core business model: Direct sales of nutrigenomic-based dietary supplements and wellness products promoting health activation through genetic pathways
- New product emphasis: Launched patent-pending MindBody GLP-1 System™ targeting gut-brain axis for appetite control and weight management
- Strategic shift: Expanded and optimized Evolve Compensation Plan globally for independent consultants, enhancing recruitment and retention efforts
- Quantitative metric: Rewards Circle loyalty program expanded to six new regions by February 2024, incentivizing subscription purchases among customers and consultants
- Noteworthy fact: Introduced technology-driven consultant engagement tools using AI and machine learning to personalize sales guidance and improve productivity
Risk Factors
- Cybersecurity risk oversight by audit committee with direct board reporting on material incidents and financial effects
- CIIO with 40+ years IT security experience leads cybersecurity program addressing risk detection and mitigation
- Potential operational disruption from cybersecurity threats managed via continuous monitoring and remediation efforts
Management Discussion & Analysis
- Cash and equivalents $20.2M at June 30, 2025, up $3.3M from $16.9M at June 30, 2024
- Net cash from operations $11.9M in FY2025 vs $12.2M in FY2024, slight decrease due to inventory and deposits
- Cash used in investing $1.4M in FY2025 for software and app development vs $2.2M in FY2024 for leasehold improvements
- Cash used in financing $7.6M in FY2025 for stock repurchases, dividends, and tax withholding vs $14.4M in FY2024
- Working capital $23.7M at June 30, 2025 vs $15.3M at June 30, 2024, driven by higher cash, inventory, and prepaid expenses
- No outstanding balance on 2024 Credit Facility as of June 30, 2025; line of credit up to $5.0M available
- Management expects current cash flow and reserves sufficient for next 12 months; may adjust capital spending or seek additional funding if needed
AI summary of the LFVN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material risk-factor changes from the June 30, 2026 Form 10-K
- Carried-forward business risks remain those disclosed in the August 27, 2026 annual filing
- Share-repurchase liquidity commitment: $60.0 million authorization through December 31, 2027
- Regulatory compliance remains governed by applicable securities laws and Rule 10b5-1 requirements
Management Discussion & Analysis
- Revenue $37.1M, down from $47.6M YoY, driven by fewer active accounts and MindBody GLP-1 declines
- Gross margin 75.4% vs 79.5%, pressured by $1.3M inventory obsolescence costs
- MindBody GLP-1 worst-performing line, sales down $4.4M; LoveBiome products partially offset declines
- Cash $13.7M, down from $14.9M; operating cash flow $0.5M vs $(2.3)M YoY
- Active accounts down 19.0% to 98,000; management expects cash and operations to fund needs for at least 12 months
AI summary of the LFVN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.07: Submission of Matters to a Vote of Security Holders
- 74.83% shareholder participation, with 9,421,295 of 12,589,444 shares represented
- All six director nominees elected, though Lewis and Beindorff received relatively narrow majorities among votes cast
Item 2.02: Results of Operations and Financial Condition
- Fiscal first-quarter results for the three months ended September 30, 2026 announced
- Investor-relevant financial figures and management commentary contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q1 FY2027 revenue $37.1M, down 22.0%, with Americas down 22.2% and Asia/Pacific & Europe down 21.2%
- Active accounts fell 19.0% to 98,000, including customers down 20.5% and independent consultants down 16.7%
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Fiscal year-end shifted from June 30 to December 31, aligning reporting with the calendar year
- Six-month transition period runs July 1, 2026 through December 31, 2026
AI summaries of LFVN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LFVN
Don't miss the next LFVN filing
- Alerts as it files. A push when LFVN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LFVN, by share count.
- Ask anything. An AI agent that reads every LFVN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| BEINDORFF MICHAEL A | Sell | Nov 12, 2026 | 10,000 | $4.89 |
| Greer Raymond B | A | Nov 5, 2026 | 17,888 | $5.87 |
| Anbalagan Rajendran | A | Nov 5, 2026 | 17,888 | $5.87 |
| BEINDORFF MICHAEL A | A | Nov 5, 2026 | 17,888 | $5.87 |
| Dayton Judd | A | Nov 5, 2026 | 17,888 | $5.87 |
| Lewis Darwin | A | Nov 5, 2026 | 17,888 | $5.87 |
| Moorehead Terrence | A | Oct 7, 2026 | 289,855 | - |
| Cunningham Kristen | A | Oct 7, 2026 | 49,275 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $228.5M | $182.6M |
| Gross Profit | - | $183.7M | $141.6M |
| Operating Income | - | $12.2M | $6.1M |
| Net Income | - | $9.8M | $5.1M |
| Gross Margin | - | 80.4% | 77.6% |
| Op. Margin | - | 5.3% | 3.3% |
| Net Margin | - | 4.3% | 2.8% |
| Balance Sheet | |||
| Total Assets | $60.3M | $72.0M | $62.1M |
| Equity | - | $34.6M | $33.6M |
| ROE | - | 28.3% | 15.1% |
| Per Share | |||
| EPS | - | $0.75 | $0.40 |
| Cash Flow | |||
| Operating CF | - | $11.9M | $10.2M |
| CapEx | $2.2M | $1.4M | $3.6M |
Source: XBRL data in Lifevantage Corp (LFVN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate LFVN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 18 | $12.5M |
| Q2 2026 | 18 | $13.7M |
| Q1 2026 | 20 | $14.3M |
| Q4 2025 | 20 | $20.7M |
| Q3 2025 | 21 | $32.5M |
| Q2 2025 | 21 | $42.4M |
| Q1 2025 | 15 | $31.4M |
| Q4 2024 | 10 | $31.0M |
- BNY Mellon+23.0K (+185%)
- Vanguard Capital Management LLC+16.1K (+4%)
- Goldman Sachs Group+10.9K (+10%)
- JPMorgan Chase & Co+3.1K (+2813%)
- AQR Capital Management−93.4K (-83%)
- Citadel Advisors LLC−52.6K (-53%)
- Renaissance Technologies LLC−39.2K (-6%)
- Millennium Management−36.9K (-52%)
- Dimensional Fund Advisors−16.9K (-7%)
- Raymond James Financial+13.4K
- FMR LLC (Fidelity)−7.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 143 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LFVN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 4 | Nov 9, 2026 | - | - | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Oct 9, 2026 | - | - | - |
| 4 | Oct 9, 2026 | - | - | - |
| 4 | Oct 9, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Oct 5, 2026 | - | Analysis | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 8-K | Aug 27, 2026 | - | Analysis | - |
| 10-K | Aug 27, 2026 | Jun 30, 2026 | - | |
| 4 | Aug 10, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
LFVN SEC filings: frequently asked questions
Are LFVN insiders buying or selling?
In the last 90 days, Lifevantage Corp (LFVN) officers, directors and 10% owners reported 1 open-market purchase worth $6,071 by 1 insider and 3 open-market sales worth $104,510 by 2 insiders on Form 4, a net sale of $98,439. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold LFVN stock?
As of September 30, 2026, the largest Lifevantage Corp (LFVN) holders among the 13F filers tracked by SignalX were Renaissance Technologies LLC ($4.0 million), Vanguard Capital Management LLC ($2.8 million), BlackRock ($1.6 million), Dimensional Fund Advisors ($1.5 million), Goldman Sachs Group ($767,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LFVN's revenue in fiscal year 2026?
For the fiscal year ended June 30, 2026 (FY2026), Lifevantage Corp (LFVN) reported revenue of $182.6 million (down 20.1% from FY2025) and net income of $5.1 million. Diluted EPS was $0.40. The figures come from the XBRL data in the 10-K.
What are the main risks in LFVN's latest 10-K?
In the 10-K filed September 4, 2025, Lifevantage Corp (LFVN) flagged: Cybersecurity risk oversight by audit committee with direct board reporting on material incidents and financial effects. CIIO with 40+ years IT security experience leads cybersecurity program addressing risk detection and mitigation. (AI summary of the Risk Factors section.)
What did LFVN report in its latest 8-K?
Lifevantage Corp (LFVN) filed an 8-K on November 12, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 74.83% shareholder participation, with 9,421,295 of 12,589,444 shares represented.
What are the latest LFVN SEC filings?
Lifevantage Corp (LFVN) filed its latest 10-K annual report on August 27, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 16, 2026.
What is LFVN's SEC CIK number?
Lifevantage Corp (LFVN)'s SEC Central Index Key (CIK) is 849146. EDGAR lists every LFVN filing under that number.
Ask anything about LFVN
The research agent reads LFVN's filings, financials, insider trades and 13F holders, then answers with sources.